One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Dianthus Therapeutics, Inc.
DNTH · NCM · Healthcare · Biotechnology
Current price
$82.38
52-week range
$32.28 - $117.88
Market cap
$4.61B
Balance sheet
Healthy
-11.04x Concerning
Net cash $885.53M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
3 Risks
0 rewards · 3 risks
- Risk Operating margin compressed from -462.9% to -8079.1% over 3 years.
- Risk Return on equity was -26.1% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 0.1% (peer median: 1.9%).
What this company does
Dianthus Therapeutics, Inc.
Dianthus Therapeutics is developing new medicines for serious autoimmune diseases, like rheumatoid arthritis or lupus, which happen when the body attacks itself. Their main income will eventually come from selling these treatments, and it matters because creating new drugs is a very long and expensive process. This company is in the early stages, meaning their drugs are still being tested and aren't ready for patients yet, so the money they have now is likely from investors funding their research.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-21.29M
FY2024 Q4
$-27.48M
FY2025 Q1
$-27.65M
FY2025 Q2
$-23.94M
FY2025 Q3
$-30.56M
FY2025 Q4
$-47.12M
FY2026 Q1
$-28.87M
FY2026 Q2
$-49.16M
Revenue
—
Net income
$-50.22M
Diluted EPS
-0.90
Operating cash flow
$-48.98M
Free cash flow
$-49.16M
Fetching…
Sources
Revenue
—
Net income
$-40.83M
Diluted EPS
-0.85
Operating cash flow
$-28.86M
Free cash flow
$-28.87M
Fetching…
Sources
Revenue
$284.00K
Net income
$-64.43M
Diluted EPS
-1.53
Operating cash flow
$-46.98M
Free cash flow
$-47.12M
Fetching…
Sources
Revenue
$396.00K
Net income
$-36.77M
Diluted EPS
-0.97
Operating cash flow
$-30.55M
Free cash flow
$-30.56M
Fetching…
Sources
Revenue
$193.00K
Net income
$-31.63M
Diluted EPS
-0.88
Operating cash flow
$-23.89M
Free cash flow
$-23.94M
Fetching…
Sources
Revenue
$1.16M
Net income
$-29.51M
Diluted EPS
-0.82
Operating cash flow
$-27.63M
Free cash flow
$-27.65M
Fetching…
Sources
Revenue
$1.33M
Net income
$-28.44M
Diluted EPS
-0.76
Operating cash flow
$-27.44M
Free cash flow
$-27.48M
Fetching…
Sources
Revenue
$2.17M
Net income
$-25.17M
Diluted EPS
-0.74
Operating cash flow
$-21.27M
Free cash flow
$-21.29M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $82.38
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $885.5M - more cash than debt. Interest coverage -11.0x.
Net debt
$-885.53M
Interest coverage
-11.04x
Dianthus Therapeutics, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 2 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
DNTH
BASELINE
Dianthus Therapeutics, Inc.
Total debt $1.29M Interest coverage -11.04x This is the baseline the peer rows are being compared against.
Total debt $162.20M Interest coverage 12.90x This peer still has a real interest-payment cushion, while DNTH does not.
Total debt $503.31M Interest coverage -1.69x Neither company has much profit cushion over interest right now.
Total debt $2.18B Interest coverage 44.28x This peer still has a real interest-payment cushion, while DNTH does not.
Total debt $3.38B Interest coverage -2.82x Neither company has much profit cushion over interest right now.
What you should know
The case for and against DNTH
0 Rewards
3 Risks
Rewards
Risks
-
Operating margin compressed from -462.9% to -8079.1% over 3 years.
-
Return on equity was -26.1% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 0.1% (peer median: 1.9%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-17.87x
P/B
3.85x
P/S
2,420.10x
EV/EBITDA
-17.10x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
100.0%
Operating margin
-8,079.1%
Net margin
0.0%
ROE
-26.1%
ROA
-17.7%
Health
Liquidity and balance-sheet strength
Debt / equity
0.00x
Current ratio
26.10x
Quick ratio
25.79x
Total debt
$1.29M
Total cash
$886.81M
Growth
How the business has been compounding
Revenue TTM
$2.04M
Revenue 5Y CAGR
—
EPS TTM
-4.24
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-155.38M
Free CF TTM
$-129.27M
FCF margin
-6,349.4%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—